Board of Directors

Arthur Tzianabos, Ph.D., has 30 years of experience in the biotechnology industry leading teams in the discovery, development, clinical translation and commercialization of new treatments for rare diseases. Most recently, Dr. Tzianabos served as President and CEO of Homology Medicines and is currently Chair of the Board. During his previous nine-year tenure at Shire, Dr. Tzianabos had an active role in the development, approval, and commercial launch of multiple therapies for patients with rare genetic disorders. He also worked closely with the Business Development and Corporate Venture functions to invest in and acquire new companies and technologies to build Shire’s pipeline. Dr. Tzianabos was an Associate Professor of Medicine at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women’s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. In addition to Homology, he is also Chair of the Board for Akouos Therapeutics, a member of the Board of Directors for both Stoke Therapeutics and Oxford Biomedica Solutions, serves on the Development Board for the University of New Hampshire’s College of Life Sciences and Agriculture and is a member of the Alliance for Regenerative Medicine’s Board of Directors and Executive Committee. He has published more than 80 scientific papers, reviews, book chapters and patents. Dr. Tzianabos holds a B.S. in Biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire.

Matt Patterson has served as a member of our Board of Directors since 2018. Mr. Patterson has served as Executive Chairman of the board of directors at Remix Therapeutics, a biotechnology company, since April 2021. Mr. Patterson is the co-founder of Audentes Therapeutics, Inc., a biotechnology company, and served in the role of Strategic Advisor from January 2020 to April 2021. Previously, he served as its Chief Executive Officer from November 2012 until Audentes’ acquisition by Astellas Pharma Inc. in January 2020. Mr. Patterson also served as Audentes’ Chairman of the board of directors and formerly served as President until May 2018. Prior to that, Mr. Patterson was the Entrepreneur-In-Residence at OrbiMed Advisors LLC. Prior to OrbiMed, Mr. Patterson served in roles at Amicus Therapeutics, Inc., BioMarin Pharmaceutical Inc. and Genzyme Corporation. Mr. Patterson serves as a director of Vor Biopharma, Inc. and 5:01 Acquisition Corp., and also serves as a director of several private companies. Mr. Patterson holds a B.A. from Bowdoin College.

Jeff Poulton has served as a member of our Board of Directors since July 2020 and serves as Lead Independent Director. Mr. Poulton has served as Executive Vice President and Chief Financial Officer at Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, since August 2019. Prior to joining Alnylam, Mr. Poulton served as Chief Financial Officer of Indigo Agriculture, a plant microbiome company, from January 2018 to April 2019, where he supported the initial commercial scale-up of the business, including expansion outside the U.S. Between 2003 and December 2017, Mr. Poulton held various roles of increasing responsibility at Shire plc, most recently as Chief Financial Officer and a member of Shire’s executive committee and board of directors from January 2015 to December 2017. During his tenure at Shire, Mr. Poulton also led Shire’s rare disease U.S., LATAM and Asia Pacific commercial operations, as well as Shire’s global rare disease business unit. Prior to Shire, Mr. Poulton led corporate finance and business development initiatives in both the gas and electric utilities industry and the materials manufacturing sector, serving in financial leadership positions at Cinergy Corp. and PPG Industries. Mr. Poulton also served in the United States Navy as a Commissioned Officer. Mr. Poulton holds a B.A. in Economics from Duke University and an M.B.A. from Indiana University.

Alise Reicin, M.D., has served as a member of our Board of Directors since July 2019. Dr. Reicin has served as Chief Executive Officer of Tectonic Therapeutic, Inc., a biotechnology company, since August 2020. Prior to Tectonic, Dr. Reicin served as President, Global Clinical Development at Celgene Corporation, a pharmaceutical company, from November 2018 to December 2019. Prior to Celgene, she served as Head of Global Clinical Development at EMD Serono, a pharmaceutical company, from May 2015 through October 2018. Prior to EMD Serono, Dr. Reicin served as VP, Program Leadership Oncology at Merck and Co., a pharmaceutical company. She holds a B.A. in Biochemistry from Barnard College of Columbia University and an M.D. from Harvard Medical School.

Steven Gillis, Ph.D., has served as a member of our Board of Directors since 2016. Since 2005, Dr. Gillis has been a managing director at ARCH Venture Partners, a venture capital firm. From 1994 to 2005, Dr. Gillis served as Chief Executive Officer and Chairman of the board of directors of Corixa Corporation, which he co-founded in October 1994. Previously, Dr. Gillis served as Director, Head of Research and Development, Chief Scientific Officer and acting Chief Executive Officer of Immunex Corporation, which he co-founded, from 1981 until his departure in 1994. As a former director and chairman of Trubion Pharmaceuticals, Inc., Dr. Gillis led its acquisition by Emergent BioSolutions in the fall 2010. Dr. Gillis currently serves as a director of Takeda Pharmaceutical Company.

Albert Seymour, Ph.D., serves as the President and Chief Executive Officer of Homology Medicines and previously served as Chief Scientific Officer. Dr. Seymour has spent more than 20 years coupling the discipline of human genetics with pharmaceutical R&D, resulting in the delivery of multiple therapeutic programs into development. At Homology, Dr. Seymour is responsible for translating the Company’s in vivo AAVHSC platform into treatments for rare disorders. Through his leadership, Homology’s phenylketonuria (PKU) program advanced from scientific concept to the world’s first gene therapy clinical trial for PKU in just under three years, in addition to building a pipeline of genetic medicine programs in late stage preclinical development. Prior to Homology, Dr. Seymour was the Senior Vice President and Global Head of Research and Nonclinical Development at Shire, where he led a team responsible for the delivery of a sustained flow of rare disease therapeutics from idea to IND and supported the full R&D portfolio in the areas of toxicology, bioanalytics and Drug Metabolism and Pharmacokinetics. Prior to that role, Dr. Seymour served as the VP and Head of Drug Discovery and Translational Research at Shire, where he doubled the rare disease discovery portfolio in three years. Before joining Shire, he spent 14 years at Pfizer leading a team in the application of human genetics and computational biology to discover and develop therapeutics and pharmacogenomics strategies in diabetes, inflammatory diseases and oncology. He is a member of the Board of Directors of Ensoma. Dr. Seymour received his undergraduate degree in Biology from the University of Delaware and M.S. degree in Molecular Biology from Johns Hopkins University, where he focused on the molecular genetics of cancer. He received his Ph.D. and post-doctoral training in human genetics at the University of Pittsburgh.

Mary Thistle has served as a member of our board of directors since 2018. Ms. Thistle has served as Special Advisor to the Bill & Melinda Gates Medical Research Institute, a non-profit biotech organization, from the fall of 2020 to June 2022, and previously served as the organization's Chief of Staff from January 2018 to the fall of2020. Prior to that, she held senior leadership positions at Dimension Therapeutics, Inc., a gene therapy company, including Chief Operating Officer from 2016 to 2017 and Chief Business Officer from 2015 to 2016. Prior to joining Dimension Therapeutics, inc., she spent six years at Cubist Pharmaceuticals, Inc., a biopharmaceutical company, where she held various leadership positions, including Senior Vice President, Business Development from 2014 to 2015, Vice President, Business Development from 2012 to 2013 and Senior Director, Business Development from 2009 to 2012. Prior to that, she held various positions at Via Cell, Inc. and PerkinElmer Inc. Ms. Thistle has served on the board of directors of Alaunos Therapeutics, Inc., formerly known as Ziopharm Oncology, Inc. since November 2020, Entrada Therapeutics, Inc. since May 2021 and Vigil Neuroscience, Inc. since April2022. Ms. Thistle holds a B.S. in Business and Accounting from the University of Massachusetts, Boston and is a former Certified Public Accountant. We believe that Ms. Thistle is qualified to serve on our board of directors due to her finance and business development background and industry experience.